medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-27-14-20medalphabet-2860Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯИнверсный псориаз и псориаз «трудных» локализаций: эффективность нетакимабаInverse psoriasis and psoriasis of ‘difficult’ localizations: Effectiveness of netakimabhttps://orcid.org/0000-0002-5044-5265КругловаЛ. С.KruglovaL. S.

Круглова Лариса Сергеевна, д.м.н., проф., зав. кафедройдерматовенерологии и косметологии

 Москва 

Kruglova Larisa S., DM Sci (habil.), professor, head of Dept of Dermatovenereology and Cosmetology 

Moscow 

kruglovals@mail.ruhttps://orcid.org/0000-0001-9638-2290РудневаН. С.RudnevaN. S.

Руднева Наталья Сергеевна, к.м.н., гл. врач, гл. внештатный специалист-дерматовенеролог, косметолог Министерства здравоохранения Тульской области, доцент кафедры пропедевтики внутренних болезней курса дерматовенерологии

Тула

Rudneva Natalya S., PhD Med, chief physician, chief freelance specialist –dermatovenereologist, cosmetologist of the Ministry of Health of the Tula region, associate professor at Dept of Propaedeutics of Internal Diseases of the course of dermatovenereology 

Tula

 

natalya.rudneva@tularegion.ruhttps://orcid.org/0000-0002-1450-4942БакулевА. Л.BakulevA. L.

Бакулев Андрей Леонидович, д.м.н., проф. кафедры дерматовенерологии и косметологии

 Москва 

Bakulev Andrey L., DM Sci (habil.), professor at Dept of Dermatovenereology and Cosmetology 

Moscow 

al_ba05@mail.ruhttps://orcid.org/0000-0002-8688-4876ХоткоА. А.KhotkoA. A.

Хотко Алкес Асланчериевич, к.м.н., зам. гл. врача по медицинской части

Краснодар 

Khotko Alkes A., PhD Med, medical deputy chief physician 

Krasnodar 

alkes@inbox.ruФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical AcademyRussian FederationГУЗ «Тульский областной клинический кожно-венерологический диспансер» Минздрава Тульской области; Медицинский институт ФГБОУ ВО «Тульский государственный университет»РоссияTula Regional Clinical Dermatovenerologic Dispensary; Medical Institute of Tula State UniversityRussian FederationГБУЗ «Клинический кожно-венерологический диспансер» Минздрава Краснодарского краяРоссияClinical Dermatovenerologic DispensaryRussian Federation202228112022127Дерматология (2)1420Copyright © Круглова Л.С., Руднева Н.С., Бакулев А.Л., Хотко А.А., 20222022Круглова Л.С., Руднева Н.С., Бакулев А.Л., Хотко А.А.Kruglova L.S., Rudneva N.S., Bakulev A.L., Khotko A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2860

Введение. Препарат нетакимаб относится к группе блокаторов ИЛ-17А и показал высокую эффективность в отношении всех клинических симптомов вульгарного псориаза, по данным клинических исследований и реальной клинической практики. В то же время данные об эффективности нетакимаба при инверсном псориазе, псориазе «трудных» локализаций носят единичный характер, при этом данные фенотипы, как правило протекают торпидно и постоянно рецидивируют, что позволяет относить их к тяжелым формам и рассматривать назначение генно-инженерных препаратов в первую линию системного лечения.Материал и методы. Под наблюдением находилось 68 пациентов с различными локализациями вульгарного псориаза (волосистая часть головы, ладони и подошвы), псориатической ониходистрофией и инверсным псориазом. Вульгарный псориаз с поражением волосистой части головы отмечался у 28 (41,2%) пациентов, с поражением ладоней и подошв – у 24 (35,3%). Инверсный псориаз был диагностирован у 37 (54,4%) пациентов. Псориатическая ониходистрофия наблюдалась у 44 (64,7%) пациентов и сочеталась как с вульгарным псориазом, так и инверсным. Всем пациентам был назначен нетакимаб.Результаты. В группе пациентов с инверсным псориазом у 81,1% пациентов через 12 недель удалось достичь sPGA 0 баллов. У 71,4% пациентов с псориазом волосистой части головы, у 75,0% с ладонно-подошвенным псориазом удалось достигнуть полного контроля над заболеванием – sPGA 0 баллов. Количество пациентов с NAPSI менее 5 баллов составило 70,5%.Вывод. Представленные в статье данные подтверждают высокую эффективность нетакимаба в лечении псориаза волосистой части головы, ладонно-подошвенного псориаза, при инверсных формах и псориатической ониходистрофии.

Introduction. The drug netakimab belongs to the group of IL-17A blockers and has shown high efficacy against all clinical symptoms of psoriasis vulgaris according to clinical trials and real clinical practice. At the same time, data on the effectiveness of netakimab in inverse psoriasis, psoriasis of ‘difficult’ localizations are of a single nature, while these phenotypes, as a rule, proceed torpidly and constantly recur, which makes it possible to attribute them to severe forms and to consider the appointment of genetically engineered drugs in the first line of systemic treatment.Material and methods. The study included 68 patients with various localizations of psoriasis vulgaris (scalp, palms and soles), psoriatic onychodystrophy and inverse psoriasis. Psoriasis vulgaris with lesions of the scalp was observed in 28 (41.2%) patients, with lesions of the palms and soles – in 24 (35.3%). Inverse psoriasis was diagnosed in 37 (54.4%) patients. Psoriatic onychodystrophy was observed in 44 (64.7%) patients and was combined with both psoriasis vulgaris and inverse psoriasis. All patients were prescribed netakimab.Results. In the group of patients with inverse psoriasis, 81.1% of patients achieved sPGA scores of 0 after 12 weeks. In 71.4% of patients with psoriasis of the scalp, in 75% of patients with palmar-plantar psoriasis, it was possible to achieve complete control over the disease sPGA 0 points. The number of patients with NAPSI less than 5 points was 70.5%.Conclusions. The data presented in the article confirm the high efficacy of netakimab in the treatment of scalp psoriasis, palmoplantar psoriasis, with inverse forms and psoriatic onychodystrophy.

псориаз трудных локализацийинверсный псориазгенно-инженерный препаратингибитор ИЛ-17нетакимабэффективностьpsoriasis of difficult localizationsinverse psoriasisgenetically engineered drugIL-17 inhibitornetakimabefficacyReferencesBardazzi F, Lambertini M, Chessa MA, Magnano M, Patrizi A, Piraccini BM. Nail involvement as a negative prognostic factor in biological therapy for psoriasis: A retrospective study. J Eur Acad Dermatol Venereol. 2017; 31 (5): 843–6.Bardazzi F, Lambertini M, Chessa MA, Magnano M, Patrizi A, Piraccini BM. Nail involvement as a negative prognostic factor in biological therapy for psoriasis: A retrospective study. J Eur Acad Dermatol Venereol. 2017; 31 (5): 843–6.Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy): nail psoriasis, effectiveness of systemic treatments. J Eur Acad Dermatol Venereol. 2011; 25 (5): 579–86.Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy): nail psoriasis, effectiveness of systemic treatments. J Eur Acad Dermatol Venereol. 2011; 25 (5): 579–86.Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020: 1–5.Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020: 1–5.van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017; 31 (3): 477–82.van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017; 31 (3): 477–82.Blauvelt A, Leonardi C, Elewski B, et al. A head- to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021; 184 (6): 1047–58.Blauvelt A, Leonardi C, Elewski B, et al. A head- to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021; 184 (6): 1047–58.Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019; 181 (5): 954–66.Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019; 181 (5): 954–66.Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009; 60(6):962–71.Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009; 60(6):962–71.Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017; 31 (12): 1999–2009.Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017; 31 (12): 1999–2009.Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021; 11 (3): 769–97.Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021; 11 (3): 769–97.Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020: 1–5.Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020: 1–5.Nakagawa H, Niiro H, Ootaki K. Japanese brodalumab study group. Brodalumab, a human anti-interleukin- 17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016; 81 (1): 44–52.Nakagawa H, Niiro H, Ootaki K. Japanese brodalumab study group. Brodalumab, a human anti-interleukin- 17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016; 81 (1): 44–52.Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double- blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017; 77 (4): 667–74.Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double- blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017; 77 (4): 667–74.Feldman SR, Green L, Kimball AB, et al. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017; 28 (8): 716–21.Feldman SR, Green L, Kimball AB, et al. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017; 28 (8): 716–21.Rompoti N, Katsimbri P, Kokkalis G, et al. Real-world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019; 32 (5): e13006.Rompoti N, Katsimbri P, Kokkalis G, et al. Real-world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019; 32 (5): e13006.Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015; 29 (9): 1763–70.Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015; 29 (9): 1763–70.Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to- severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017; 28 (4): 282–7.Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to- severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017; 28 (4): 282–7.Langley RG, Papp K, Gooderham M, et al. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderateto-severe plaque psoriasis in a randomized phase III trial (IXORA-P). Br J Dermatol. 2018; 178 (6): 1315–23.Langley RG, Papp K, Gooderham M, et al. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderateto-severe plaque psoriasis in a randomized phase III trial (IXORA-P). Br J Dermatol. 2018; 178 (6): 1315–23.Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018; 56 (6): 392–8.Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018; 56 (6): 392–8.Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020; 82(1): 117–22.Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020; 82(1): 117–22.Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double- blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018; 179 (4): 844–52.Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double- blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018; 179 (4): 844–52.Ješe R, Perdan-Pirkmajer K, Dolenc-Voljč M, Tomšič M. A case of inverse psoriasis successfully treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat. 2014; 23 (1): 21–3.Ješe R, Perdan-Pirkmajer K, Dolenc-Voljč M, Tomšič M. A case of inverse psoriasis successfully treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat. 2014; 23 (1): 21–3.Campos MA, Varela P, Baptista A, Moreira AI. Inverse psoriasis treated with ustekinumab. BMJ Case Rep. 2016; 2016 https://doi.org/10.1136/bcr-2016–215019.Campos MA, Varela P, Baptista A, Moreira AI. Inverse psoriasis treated with ustekinumab. BMJ Case Rep. 2016; 2016 https://doi.org/10.1136/bcr-2016–215019.Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017; 31 (10): 1686–92.Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017; 31 (10): 1686–92.Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017; 76 (1): 70–80.Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017; 76 (1): 70–80.Круглова Л. С., Бакулев А. Л., Коротаева Т. В., Лила А. М., Переверзева Н.О. Псориаз. ГЭОТАР-Медиа. 2022. 328 с.Kruglova L.S., Bakulev A.L., Korotaeva T.V., Lila A.M., Pereverzeva N.O. Psoriasis. GEOTAR-Media. 2022. 328 p.Хотко А.А., Круглова Л.С., Помазанова М.Ю., Хотко Р.А. Эффективность препарата нетакимаб в реальной клинической практике у пациентов с тяжелыми формами псориаза. Медицинский алфавит. 2020. 6 (420). Том № 1. С. 28–34.Hotko A.A., Kruglova L.S., Pomazanova M. Yu., Hotko R.A. Efficacy of netakimab in real clinical practice in patients with severe forms of psoriasis. Medical Alphabet. 2020. 6 (420). Volume No. 1. P. 28–34.

The authors declare that there are no conflicts of interest present.